Macmillan Cancer Support has launched a new £30 million investment fund aimed at accelerating innovation and transforming cancer care across the United Kingdom. The initiative, operating through Macmillan Ventures, will invest in early-stage healthcare and technology startups developing solutions that can improve cancer diagnosis, treatment, care delivery, and long-term patient support.
The new fund follows the successful completion of Macmillan’s earlier £3.5 million pilot impact investment programme, which supported several pioneering companies focused on technology-enabled cancer care solutions. The charity plans to deploy the larger fund over the next five years, targeting innovations that address some of the biggest challenges facing cancer patients and healthcare systems.
Macmillan Ventures is particularly interested in technologies that improve early diagnosis, reduce inequalities in cancer care, enhance patient experiences, and shift more healthcare delivery into local communities. Areas of focus include digital health platforms, AI-powered diagnostics, treatment innovation, and tools that help people live better during and after cancer treatment.
The charity says the investment strategy reflects growing concern about pressures facing cancer care services in the UK. Macmillan research indicates that millions of people living with cancer continue to experience gaps in emotional, physical, and practical support while healthcare systems face staffing shortages and increasing demand.
The investment programme is supported by philanthropists, healthcare experts, and corporate partners who aim to help modernize cancer services and improve long-term outcomes for patients. Macmillan believes combining charitable insight with venture-style investment can help bring promising healthcare innovations into real-world use more quickly.
